Funding growth The institute recently secured multi-million federal and state funding (4.2M federal expansion, 2.5M CREST grant) and plans facility upgrades, signaling expanding research capacity and potential demand for enhanced lab instruments, compliance services, and facility services.

Expansion readiness Recent investments to expand and modernize research facilities indicate readiness for new collaborations, contract research, and sponsored projects with industry partners seeking access to advanced immunology and infectious disease platforms.

Public‑private partnerships Strategic collaborations with Walter Reed, SUNY Upstate, Albert Einstein, and other biopharma and non‑profits suggest opportunities for technology licensing, joint development programs, and clinical translation partnerships.

Education outreach Active education programs and summer research initiatives demonstrate a pipeline for talent sourcing, potential collaboration on training programs, and opportunities to deploy training-centric solutions or services.

Combatting pathogens Focus on tuberculosis, SARS‑CoV‑2, Zika, influenza, and Powassan virus positions the institute as a strategic partner for diagnostic, therapeutic, and bioassay development, with potential demand for research reagents, partnerships, and rapid testing capabilities.